ArticleJournal of gastrointestinal oncology2013
Can only chemoradiotherapy and chemotherapy treatment be applied to patients with rectal cancer who could not be operated?
Article in Journal of gastrointestinal oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study is aimed to evaluate patients with non-metastatic rectal cancer who could not be operated due to any reason and were treated with chemoradiotherapy alone or chemotherapy following chemoradiotherapy.
methodsPatients with locally advanced non-metastatic rectal cancer, who were treated and followed-up were evaluated.
resultsTotally 263 patients with stage II and III rectal cancer were evaluated. It was determined that 14 (5.2%) of the patients with locally advanced stages received chemoradiotherapy alone or chemotherapy following chemoradiotherapy, and they were followed-up instead of undergoing operation. The baseline assessments revealed that 8 (57.1%) patients had clinical stage II, and 6 (42.9%) patients had clinical stage III diseases. Recurrence was detected in 3 (21.4%) patients. 6 (42.9%) patients died, and death due to rectal cancer progression was detected in 2 (14.3%) patients. Median progression-free survival was 25 months (8 to 68 months), median overall survival was 35 months (12 to 68 months), overall survival rates in 1, 3 and 5 years were 92.9%, 69.8% and 52.4%, respectively.
conclusionsChemoradiotherapy alone or subsequent chemotherapy after chemoradiotherapy may be suitable for patients with non-metastatic locally advanced rectal cancer who could not be operated due to any reason.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.